Antidiabetic effect of chronic administration of JTT-608, a new hypoglycemic agent, in diabetic Goto-Kakizaki rats

European Journal of Pharmacology

Volumn 476, Issue 1-2, 2003, Pages 159-166

  Ohta, Takeshi ^a   Miyajima, Katsuhiro ^a   Komuro, Goro ^a   Furukawa, Noboru ^a   Yonemori, Fumihiko ^a  

^a JAPAN TOBACCO INC   (Japan)

Author keywords

Antidiabetic agent; Goto Kakizaki rat; Hemoglobin A1c; JTT 608; Nephropathy; Neuropathy

Indexed keywords

4 (4 METHYLCYCLOHEXYL) 4 OXOBUTYRIC ACID; 4 (METHYLCYCLOHEXYL) 4 OXOBUTYRIC ACID; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; GENETIC MODEL; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HISTOPATHOLOGY; KIDNEY TUBULE; MOTOR NERVE CONDUCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0142169473     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)02120-4     Document Type: Article

References (39)

1. Agardh C.D., Agardh E., Zhang H., Östenson C.D. Altered endothelial/pericyte ratio in Goto-Kakizaki rat retina. J. Diabetes its Complicat. 11:1997;158-162.
2. Antonio E.P., Anna C., Guido P. Secondary failure of oral hypoglycaemic agents: frequency, possible causes, and management. Diabetes Metab. Rev. 10:1994;31-43.
3. Aspuland K., Wiholm B.E., Lithner F. Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia. 24:1983;412-417.
4. Defronzo R.A. Pharmacologic therapy for type 2 diabetes mellitus. Ann. Intern. Med. 131:1999;281-303.
5. Delprato S., Tiengo A. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus. Diabetes Metab. Res. Rev. 17:2001;164-174.
6. Dunber J.C., Foa P.P. An inhibitory effect of tolbutamide and glibenclamide (glyburide) on the pancreatic islets of normal animals. Diabetologia. 10:1974;27-35.
7. Ferner R.E., Neil H.A.W. Sulphonylureas and hypoglycaemia. Br. Med. J. 296:1988;949-950.
8. Furukawa N., Ohta T., Noguchi T., Yonemori F., Wakitani K. Glucose-dependent insulinotropic effects of JTT-608, a novel antidiabetic compound. Eur. J. Pharmacol. 371:1999;51-58.
9. Gerich J.E. Oral hypoglycemic agents. N. Engl. J. Med. 321:1989;1231-1245.
10. Goto Y., Kakizaki M., Yagihashi S. Neurological findings in spontaneously diabetic rats. Excepta Med. Int. Cong. Ser. 581:1982;26-38.
11. Groop L.C. Sulfonylureas in NIDDM. Diabetes Care. 15:1992;737-754.
12. Harrower A.D.B. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. J. Diabetes its Complicat. 8:1994;201-203.
13. Home P. La régulation du glucose prandial est-elle importante dans le diabéte de type 2? Diabetes Metab. (Suppl. 7):1999;20-21.
14. Ido Y., Mchowat J., Chang K.C., Arrigoni-martelli E., Orfalian Z., Kilo C., Corr P.B., Williamson J.R. Neural dysfunction and metabolic imbalances in diabetic rats. Prevention by acetyl-L-carnitine. Diabetes. 43:1994;1469-1477.
15. Kawai K., Suzuki S., Murayama Y., Watanabe Y., Yamashita K. Comparison of B-cell function after long-term treatment with either insulin, insulin plus gliclazide or gliclazide in neonatal streptozotocin-induced non-insulin- dependent diabetic rats. Diabetes Res. Clin. Pract. 12:1991;163-172.
16. Kosaka K., Kuzuya T., Hagura R. Insulin secretory response in Japanese type 2 (non-insulin-dependent) diabetic patients. Diabetes Res. Clin. Pract. 24:1994;S101-S110.
17. Lam N.T., Kieffer T.J. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent. Minerva Endocrinol. 27:2002;79-93.
18. Landgraf R. Approaches to the management of postprandial hyperglycaemia. Exp. Clin. Endocrinol. Diabetes. 107(Suppl. 4):1999;S128-S132.
19. Lehmann R. The significance of postprandial glycemia. Schweiz. Rundsch. Med. PRAXIS. 90:2001;345-348.
20. Leibowitz G., Cerasl E. Sulphonylurea treatment of NIDDM patients with cardiovascular diseases: a mixed blessing? Diabetologia. 39:1996;503-514.
21. Miyoshi T., Goto I. Serial in vivo determinations of nerve conduction velocity in rat tails: physiological and pathological changes. Electroencephalogr. Clin. Neurophysiol. 35:1973;125-131.
22. Movassat J., Saulnier C., Serradas P., Portha B. Impaired development of pancreatic beta-cell mass is a primary event during the progression to diabetes in the GK rat. Diabetologia. 40:1997;916-925.
23. 2+ influx by phosphodiesterase inhibition. Br. J. Pharmacol. 129:2000;901-908.
24. Ohta T., Furukawa N., Yonemori F., Wakitani K. JTT-608 controls blood glucose by enhancement of glucose-stimulated insulin secretion in normal and diabetes mellitus rats. Eur. J. Pharmacol. 367:1999;91-99.
25. Ohta T., Furukawa N., Komuro G., Yonemori F., Wakitani K. JTT-608 restores impaired early insulin secretion in diabetic Goto-Kakizaki rats. Br. J. Pharmacol. 126:1999;1674-1680.
26. Östenson C.G., Fiere V., Ahmed M., Lindstrom P., Brismar K., Brismar T., Kreicbergs A. Decreased cortical bone thickness in spontaneously non-insulin-dependent diabetic GK rats. J. Diabetes its Complicat. 11:1997;319-322.
27. Shibata T., Takeuchi S., Yokota S., Kakimoto K., Yonemori F., Wakitani K. Effect of peroxisome prolifertor-activated receptor-α and -γ agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. Br. J. Pharmacol. 130:2000;495-504.
28. Shinkai H., Ozeki H., Motomura T., Ohta T., Furukawa N., Uchida I. 4-(trans-4-Methylcyclohexyl)-4-oxobutyric acid (JTT-608). A new class of antidiabetic agent. J. Med. Chem. 41:1998;5420-5428.
29. Sodoyers J.C., Sodoyers-Goffaux F., Dunbar J.C., Foa P.P. Reduction in the activity of the pancreatic islets induced in normal rodents by prolonged treatment with derivatives of sulfonylurea. Diabetes. 19:1970;603-609.
30. Sone H., Kawakami Y., Okuda Y., Sekine Y., Honmura S., Matsuo K., Segawa T., Suzuki H., Yamashita K. Ocular vascular endothelial growth factor levels in diabetic rats are elevated before observable retinal proliferative changes. Diabetologia. 40:1997;726-730.
31. Spüler M., Dimpfel W., Tüller H.U. Effect of gangliosides on nerve conduction velocity during diabetic neuropathy in the rat. Arch. Int. Pharmacodyn. Ther. 287:1987;211-223.
32. Sugiyama Y., Okada H., Shimura Y., Ikeda H., Matsuo T., Abe S., Suzuki K., Goto Y. Role of hepatic insulin sensitivity in development of hyperglycemia of spontaneously diabetic GK rats. J. Jpn. Diab. Soc. 32:1989;593-599.
33. Turner R.C. The U.K. Prospective diabetes study. a review. Diabetes Care. (Suppl. 3):1998;35-38.
34. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 281:1999;2005-2012.
35. Vesely D.L., Gower W.R., Dietz J.R., Overton R.M., Clark L.C., Antwi E.K., Farese R.V. Elevated atrial natriuretic peptides and early renal failure in type 2 diabetic Goto-Kakizaki rats. Metabolism. 48:1999;771-778.
36. Wada R., Koyama M., Mizushima H., Okada H., Ikeda H., Yagihashi S. Effects of long-term treatment with alpha-glucosidase inhibitor on the peripheral nerve function and structure in Goto-Kakizaki rats: a genetic model for type 2 diabetes. Diabetes Metab. Res. Rev. 15:1999;332-337.
37. William C.D., Solomon S.S., Abbas E.K. Effect of chronic sulfonylurea therapy on plasma insulin and proinsulin levels. J. Clin. Endocrinol. Metab. 35:1972;585-591.
38. Yagihashi S., Goto Y., Kakizaki M., Kaseda N. Thickening of glomerular basement membrane in spontaneously diabetic rats. Diabetologia. 15:1978;309-312.
39. Yagihashi S., Tonosaki A., Yamada K., Kakiaki M., Goto Y. Peripheral neuropathy in selectively-inbred spontaneously diabetic rats: electrophysiological, morphometrical and freeze-replica studies. Tohoku J. Exp. Med. 138:1982;39-48.